Replies to post #75137 on Biotech Values

[DewDiligence]

A Tribute to Genentech / addendum: If you have not already taken the survey in #msg-36329285, please do so.

[Preciouslife1]

Hematology: Rituximab in follicular lymphoma

http://www.nature.com/nrclinonc/journal/v6/n4/full/nrclinonc.2009.6.html
Nature Reviews Clinical Oncology 6, 186 (April 2009) | doi:10.1038/nrclinonc.2009.6
Mandy Aujla

Original article Salles, G. et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112, 4824–4831 (2008). PubMed


There is currently no standard first-line chemotherapy regimen for the treatment of patients with follicular lymphoma. A recent study by Gilles Salles et al. has shown that the combination of rituximab and chemotherapy plus interferon-alpha provides superior disease control when compared with chemotherapy plus interferon-alpha alone in the first-line treatment of patients with follicular lymphoma and high tumor burden.

Follicular lymphoma is the second most common lymphoma to occur in adults and several studies have shown that the combination of interferon-alpha with anthracycline-containing chemotherapy can improve survival. The humanized monoclonal anti-CD20 antibody, rituximab, has shown promise to treat follicular lymphoma—when used as a single agent, and also when used in combination with chemotherapy. Preliminary data have also suggested that interferon-alpha could further enhance the activity of rituximab. This finding led the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and the Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS) to investigate the potential benefit of rituximab in combination with chemotherapy and interferon in patients with follicular lymphoma.

This multicenter, randomized study included patients aged between 18 and 75 years with a diagnosis of follicular lymphoma by a lymph node biopsy. The researchers randomly assigned patients to receive either 12 courses of the chemotherapy regimen consisting of cyclophosphamide, adriamycin, etoposide and prednisolone (CHVP, n = 183) plus interferon-alpha over 18 months, or 6 courses of the same CHVP regimen combined with 6 infusions of rituximab and interferon-alpha for the same time period (n = 175). Salles et al. presented their analysis of this study after a median of 5 years of follow-up.

Between May 2000 and May 2002, 358 patients were considered eligible for inclusion, and data from these patients were analyzed. After 5 years of follow-up, event-free survival was estimated to be 37% in the chemotherapy arm and 53% in the rituximab arm; there was no statistically significant difference in overall survival between the two treatment arms. Despite the shorter duration of treatment, the combination of CHVP plus rituximab improved the outcome of patients with follicular lymphoma compared with treatment with CHVP plus interferon alone. The long follow-up period in this study confirms that the response to the rituximab treatment regimen is also substantially prolonged. "One of the most significant findings from the FL2000 study is the durability of the benefit observed in patients receiving the combination of rituximab with chemotherapy plus interferon," says Salles. "Indeed, more than 3 years after the last infusion of the anti-CD20 monoclonal antibody, more patients are experiencing a sustained response with this combination as compared to those that received chemotherapy plus interferon only."

The authors suggest that the use of rituximab in combination with chemotherapy should become the new standard for patients with follicular lymphoma with a high tumor burden.


PL1

[Preciouslife1]

Roche says Genentech's Levinson to stay on board
Tue Apr 14, 2009 7:53pm EDT

http://www.reuters.com/article/innovationNews/idUSN1445665420090414

LOS ANGELES (Reuters) - Roche Holding AG (ROG.VX), which last month acquired Genentech Inc, said on Tuesday that Arthur Levinson, the biotech company's chief executive, would stay on as chair of a new Genentech board.

Levinson will no longer be CEO, but will be charged with steering integration of the two companies, serve as a scientific adviser and be nominated to the Roche board, the Swiss company said in a statement.

Roche has appointed several of its own executives to top non-research positions at Genentech as of May 1, including Pascal Soriot as CEO.

Roche said Susan Desmond-Hellmann, president of product development at Genentech, will hand over her responsibilities by mid-year, after which she will also act as an adviser to the company and join the scientific advisory board.

During the eight-month-long takeover battle that ended in March, Roche had said it expected Genentech senior management to stay on, but some shareholders and analysts have surmised that the biotech company's prolific scientists and top managers would view the acquisition as an opportunity to leave.

Roche said Richard Scheller, executive vice president of Genentech research, will lead an independent research and development group within Roche, which will report directly to Chief Executive Severin Schwan.

Roche also said that William Burns, CEO of the Roche pharmaceutical group, will retire next January 1 and will also be nominated to the company's board.

In addition, Marc Tessier-Lavigne, currently executive vice president of Genentech research drug discovery, will succeed Scheller as head of research and be appointed as Genentech's chief scientific officer.

On the commercial side, Roche said Soriot, currently responsible for operations of the pharmaceutical division at Roche, will be appointed as CEO of Genentech, where he will lead all pharma activities in the United States.

Ian Clark, head of commercial operations at Genentech, will take over as head of global marketing and chief marketing officer for Roche's entire pharmaceutical division.

Pat Yang will continue as head of technical operations at Genentech, while Hal Barron, currently head of Genentech development and chief medical officer, will become head of global development for oncology, immunology/tissue growth repair and virology.

Roche said David Ebersman, Genentech's chief financial officer, and Steve Juelsgaard, chief compliance officer, will be leaving the company.